Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure

• Published in: The American journal of cardiology Vol. 83; no. 6; pp. 969 - 971
• Main Authors: Spargias, Konstantinos S., Lindsay, Steven J., Hall, Alistair S., Cowan, J.Campbell, Ball, Stephen G.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15.03.1999; Elsevier; Elsevier Limited
• Subjects: Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Biological and medical sciences; Cardiology; Cardiovascular system; Drug therapy; Electrocardiography - drug effects; Female; Heart attacks; Heart failure; Heart Failure - etiology; Humans; Male; Medical sciences; Middle Aged; Myocardial Infarction - complications; Myocardial Infarction - drug therapy; Myocardial Infarction - physiopathology; Pharmacology. Drug treatments; Ramipril - therapeutic use; Single-Blind Method; Vasodilator agents. Cerebral vasodilators; Vasodilator agent; Infarct; Arrhythmia; Cardiovascular disease; Ramipril; Myocardial disease; Prevention; Electrodiagnosis; Peptidyl-dipeptidase A; Heart disease; Electrocardiography; Complication; Mechanism of action; Human; Heart failure; QT interval; Enzyme; Acute; Enzyme inhibitor; Coronary heart disease; Peptidases; Chemotherapy; Treatment; Myocardium; Hydrolases; Peptidyl-dipeptidases
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/S0002-9149(98)01049-2

In a cohort of 67 patients from the Acute Infarction Ramipril Efficacy study, we showed that ramipril therapy was associated with a significant reduction in QT dispersion over a 2-month period after acute myocardial infarction. This reduction of ventricular repolarization inhomogeneity indicates an antiarrhythmic effect and may be an important additional mechanism for the reduced all-cause mortality and sudden death incidence achieved with angiotensin-converting enzyme inhibition after acute myocardial infarction.